Fluspirilene, an anti-psychotic drug, has been identified as a cancer drug candidate due to its ability to bind to murine double minute 2 (MDM2), potentially blocking the interaction between p53 and MDM2 [92]. The gene discussed is MDM2; the disease is cancer.